22OCT

CuspAI closes at $2.6bn, EU fund circles

2 min read

16:30UTC

CuspAI closed in late June at $2.6bn with Bezos Expeditions and Kleiner Perkins and no UK backer; now EQT and the EU's Scaleup Europe Fund want in.

← Back to Stryker agrees option to buy CMR Surgical Jump to analysis ↓

TechnologyDeveloping

Key takeaway

An EU sovereign fund is circling a UK AI winner that no British investor backed.

CuspAI's round formally closed in late June at a $2.6bn valuation, led by Bezos Expeditions and Kleiner Perkins, with no UK vehicle on the cap table⁠¹. The Cambridge materials-discovery firm, which uses AI to design new materials, had signed those term sheets on 20 June; the close confirms the figure without moving it.

EQT, the Swedish investment group the European Innovation Council (the EU's deep-tech funding body) appointed to run the bloc's new €5bn Scaleup Europe Fund, then entered advanced talks for a further CuspAI stake, reported on 3 July⁠².

Britain spent the spring building sovereign vehicles to stop allied capital capturing its AI winners, after Fractile raised NATO and CIA venture money with no UK co-investor and Orbital Industries closed $50m with no UK lead. EQT would put an EU vehicle, not a US one, on the cap table of a company Britain's own funds passed over. The Scaleup Europe Fund holds €5bn; the UK's Sovereign AI Unit holds £500m, and has led none of the marquee 2026 rounds.

Deep Analysis

In plain English

CuspAI is a Cambridge company that uses artificial intelligence to design new materials, such as ones that capture carbon or remove harmful chemicals from water. It has just finished raising $2.6bn worth of shares from investors, but none of that money came from a British fund. Now EQT, a European investment firm managing €5bn of European Union government money, wants to buy an even bigger stake. 'No UK vehicle on the cap table' means no British-based investor owns a piece of the company. As CuspAI grows, the profits from its success will flow mostly to American and European investors rather than back into the UK.

Deep Analysis

Root Causes

The UK lacks a domestic growth-equity fund capable of writing $200m-plus cheques at Series C and beyond for deep tech. British Patient Capital, the British Business Bank's growth vehicle, is structured to allocate as a limited partner into other funds rather than write large direct cheques itself, so when a round the size of CuspAI's needs $400m in a single close, only sovereign wealth vehicles or US mega-funds have the balance sheet to supply it.

That capacity gap, not a lack of UK investor appetite, is why EQT's EU-backed fund can enter talks for a further stake while no comparable British vehicle appears on the term sheet.

What could happen next?

Precedent
EQT's pursuit of a CuspAI stake sets a template for EU sovereign vehicles buying into UK deep-tech winners at the exact cheque size domestic funds cannot match.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: ARM's 2016 sale to SoftBank showed the same mechanism at a bigger scale: a Cambridge deep-tech company with no domestic institution large enough to anchor it at its true valuation, so ownership passed abroad once the cheque size exceeded what UK growth capital could write.

Counter-parallel: Wise scaled to a London direct listing in 2021 with Baillie Gifford, a Scottish asset manager, as a top-five shareholder throughout, proving domestic capital can anchor a major scale-up when a UK institution commits early enough in the company's life, before the round sizes outgrow it.

The immediate effect is straightforward: none of CuspAI's future dividends, exit proceeds or tax receipts from a sale accrue disproportionately to UK-domiciled capital, because no UK fund holds equity to realise a gain on.

Structurally, this repeats a pattern across the fortnight's largest UK deep-tech rounds: British companies are increasingly financed by allied sovereign and foreign venture capital rather than domestic institutions, which means the country builds the technology but exports the equity upside.

Consensus view: Atomico's Tom Wehmeier, author of the annual State of European Tech report, reads EQT's Scaleup Europe Fund pursuit of CuspAI as deliberate EU industrial policy: the €5bn vehicle exists specifically to keep deep-tech winners like CuspAI anchored in Europe once a round like June's $2.6bn close shows a company can scale without a domestic lead.

Counter-view: The Startup Coalition, the UK industry body representing founders, argues the absence of a UK vehicle reflects a structural gap in domestic late-stage capital rather than EU strategy, the same gap that let the NATO Innovation Fund and In-Q-Tel into Fractile's cap table and Plural's European balance sheet into Orbital Industries with no UK fund on either.

Key tension: Whether EQT's approach substitutes for a UK vehicle that will never exist at this cheque size, or entrenches a pattern where Britain's largest deep-tech winners are permanently owned from Stockholm, Washington and Palo Alto rather than London.

First Reported In

Update #10 · AI takes record 44% as UK equity shrinks

FinSMEs / Sifted / FTI Consulting digest· 4 Jul 2026

Read original →

Causes and effects

Caused by

CuspAI raising $400m on Bezos money

CuspAI's late-June close confirms the $2.6bn valuation set when term sheets were signed on 20 June.

Occurred 20 Jun 2026

Read story →

Fractile lands NATO and CIA chip cash

Fractile's NATO/CIA-backed round with no UK co-investor set the precedent of allied capital capturing UK deep-tech upside, now repeated with EQT and CuspAI.

Occurred 13 May 2026

Read story →

Orbital's $50m raise has no UK lead

Orbital Industries' $50m round with no UK lead extended the pattern of foreign capital capturing UK deep-tech winners, now repeated with EQT's pursuit of CuspAI.

Occurred 28 May 2026

Read story →

This Event

CuspAI closes at $2.6bn, EU fund circles

If EQT closes, the upside of a UK AI winner accrues to an EU sovereign fund, the exact outcome Britain's own vehicles were built to prevent.

Led to

State fund surfaces on CuspAI cap table

The 3 July report of a round closed with no UK vehicle is contradicted by the 20 July naming of the Sovereign AI Unit as a new investor.

Occurred 20 Jul 2026

Read story →

Different Perspectives

Abu Dhabi Investment Council

The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.

CDP Venture Capital

CDP Venture Capital, the venture arm of Italy's state lender, led TrueLayer's £20.4m round to expand Pay by Bank across Europe. A foreign state investor set the terms on a London fintech round in the same month the British Business Bank mostly followed.

EDBI

Singapore's state investor EDBI joined Universal Quantum's Series A of more than $100m, and the Sussex company is opening its first research centre outside Europe in Singapore. British state money is absent from the largest Series A by a UK quantum company.

Forbion

Forbion co-led OMass Therapeutics' $310m Series C with Bain Capital Life Sciences and Novo Holdings, while the British Business Bank and Syncona followed. The terms of the Oxford spinout's round were set by investors from three countries, none of them Britain.

British Business Bank

The Bank committed £180m to six AI funds on 15 October with no UK-deployment condition, yet led the first close of Microbiotica's £36m Series C. That lead, with Airtel Money choosing London for its £5.3bn debut, is the evidence that British money and markets still set some terms.

Stryker Corporation

Stryker called its roughly $400m CMR Surgical deal its entry into soft-tissue robotics, taking US sales rights for Versius, a board seat and an exclusive option over 100% of the company. The option lets Stryker choose whether and when a Cambridge robot maker becomes part of an American group.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.